A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults

Trial Profile

A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs MG 1111 (Primary) ; Varicella zoster virus vaccine live
  • Indications Varicella zoster virus infections
  • Focus Adverse reactions
  • Sponsors Green Cross
  • Most Recent Events

    • 02 Sep 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.
    • 24 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top